Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort


Olsson T., Achiron A., Alfredsson L., Berger T., Brassat D., Chan A., ...More

MULTIPLE SCLEROSIS JOURNAL, vol.19, no.11, pp.1533-1538, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 11
  • Publication Date: 2013
  • Doi Number: 10.1177/1352458513477925
  • Title of Journal : MULTIPLE SCLEROSIS JOURNAL
  • Page Numbers: pp.1533-1538

Abstract

JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.